Innovative vaccine approaches employing synergistic adjuvant combinations and antibody engineering demonstrate breakthrough efficacy. Research teams at MIT and the Scripps Research Institute unveiled a supercharged vaccine leveraging alum and a saponin-based nanoparticle that elicits robust, enduring immune activation with a single dose, bolstering antibody breadth and potency against HIV and other pathogens. Genentech and other companies disclose novel splicing modulators and dual antibody conjugates designed to increase efficacy and target solid tumors more effectively, fueling the next wave of biologic therapeutics.